Aims: Increases in protein kinase C (PKC) and oxidative stress have been related to mania. Drugs with antioxidant effects or inhibitory actions on PKC may have antimanic effects. The flavonoid quercetin has antioxidant and PKCinhibiting effects that resemble those of lithium, the first-line treatment for mania in bipolar disorder. We hypothesized that quercetin may have antimanic-like effects in an animal model. Main methods: In the present study, we investigated the effects of acute and chronic treatment with quercetin (2.5, 5, 10, and 40 mg/kg, i.p.) in male Swiss mice that were subjected to methylphenidate (5 mg/kg, i.p.)-induced hyperlocomotion, an animal model of mania. Lithium (100 mg/kg, i.p.) and diazepam (5 mg/kg, i.p.) were used as positive and negative controls, respectively. We also evaluated the effects of these treatments on methylphenidate-induced oxidative stress in the brain by measuring reduced glutathione (GSH) and lipid peroxidation (LPO) levels in the prefrontal cortex, hippocampus, and striatum. Key findings: Acute and chronic (21-day) treatment with lithium and diazepam reduced methylphenidateinduced hyperlocomotion. Chronic but not acute treatment with quercetin (10 and 40 mg/kg) blocked methylphenidate-induced hyperlocomotion. These effects of lithium and quercetin occurred at doses that did not alter spontaneous locomotor activity, whereas diazepam reduced spontaneous locomotor activity. Chronic treatment with lithium and quercetin blocked the methylphenidate-induced increase in LPO levels in the striatum. Significance: These results suggest that chronic quercetin treatment has antimanic-like and antioxidant effects, thus encouraging further studies of quercetin as a putative new antimanic drug.
Introduction
Manic episodes in bipolar disorder (BD) are treated with mood stabilizers (e.g., lithium), atypical antipsychotics (e.g., risperidone), and anticonvulsants (e.g., sodium valproate), but their management in clinical settings remains a challenge [1, 2] . Mania has been related to oxidative stress [3, 4] and increased activity of protein kinase C (PKC) [5, 6] . Lithium and sodium valproate, which are the most frequently used antimanic drugs, exert antimanic effects via PKC inhibition and/or antioxidant activity [6, 7, 8, 9, 6, 10] .
One animal model that is employed to induce manic-like behavior involves the administration of psychostimulants, such as methylphenidate. The pharmacological induction of manic-like behavior (e.g., hyperlocomotion) is relatively easy to generate and test and has reliability and validity. Locomotor activity is known to increase in manic patients [11] . Mines et al. [12] showed that methylphenidate, which blocks dopamine and noradrenaline transporters (DAT and NET respectively) enhancing dopamine (DA) and noradrenaline (NA) synaptic levels, increased locomotor activity in mice, and this effect was blocked by sodium valproate, carbamazepine, and lithium at doses that did not impair spontaneous locomotor activity [13, 14, 15, 16, 17, 18] .
Quercetin is a flavonoid that possesses antioxidant properties [19] and inhibits PKC [20] . We hypothesized that quercetin might also have antimanic-like effects. A previous study found that acute administration of quercetin blocked both hyperlocomotion and oxidative stress that were induced by sleep deprivation [21] . However, this previous study administered quercetin only acutely and employed only one model, which may have resulted in false-positive results. Quercetin has already been tested in a clinical trial of its anti-inflammatory effects [22] , indicating its therapeutic utility. The objective of the present study was to evaluate the effects of acute and chronic quercetin administration on methylphenidate-induced hyperlocomotion and oxidative stress in the brain in mice.
Material and methods

Animals
The study included male Swiss mice, weighing 30-40 g, that were housed at 22°C ± 2°C under a 12 h/12 h light/dark cycle (lights on at 7:00 AM). The animals were kept in polypropylene cages (41 cm × 34 cm × 16 cm) with food and water available ad libitum. All of the experiments were approved by the Committee of Animal Experimentation of the Federal University of Paraná (CEUA/BIO-UFPR, protocol no. 733) and conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health).
Drugs
The mice were treated with saline (0.9% NaCl; 10 ml/kg, i.p.), lithium carbonate (Eurofarma, Brazil; positive control; 100 mg/kg, i.p., dissolved in saline, with the pH adjusted to 7.4 with hydrochloric acid), diazepam (Cristália, Brazil; 5 mg/kg, i.p., dissolved in distilled water), or quercetin (Sigma, St. Louis, MO, USA; 2.5, 5, 10, or 40 mg/kg, i.p., suspended in 0.5% carboxymethylcellulose [CMC] ). Methylphenidate (Novartis, São Paulo, SP, Brazil) was dissolved in saline and administered subcutaneously (s.c.) at a dose of 5.0 mg/kg. The drugs were administered in a volume of 10 ml/kg of body weight. The doses were based on data from the literature [23] and previous studies by our research group [13, 21, 24] . Chronic treatment with lithium, diazepam, and quercetin was performed once per day for 21 days.
Methylphenidate-induced hyperlocomotion protocol
In the acute treatment protocol, the animals were pretreated with lithium, diazepam, quercetin, or vehicle 15 min before the administration of either vehicle or methylphenidate (Fig. 1, top) . In the chronic treatment protocol, the animals were pretreated with lithium, diazepam, quercetin, or vehicle once per day for 21 days. On the test day, vehicle or methylphenidate was administered 15 min after the last administration of lithium, diazepam, quercetin, or vehicle (Fig. 1,  bottom) .
Twenty minutes after vehicle or methylphenidate administration, the animals were individually placed in an automated activity box (40 cm × 20 cm × 26 cm) that was constructed from wood with a wire mesh floor. The box had three photoelectric sensors (10 cm apart) on the two longer lateral walls. The number of crossings was cumulatively recorded by photoelectric sensors over a 20 min period. The number of crossings was considered an index of locomotor activity. An increase in the number of crossings after methylphenidate administration indicated a stimulant effect. The blockade of the stimulant effect of methylphenidate at a dose that did not decrease spontaneous locomotor activity indicated an antimanic-like effect [24, 25] .
Evaluation of oxidative stress parameters in the mouse brain
Brain samples
The mice were euthanized by decapitation immediately after being exposed to the automated activity box. The prefrontal cortex (PFC), hippocampus, and striatum were dissected, frozen in liquid nitrogen, and stored at −80°C until further analysis. The samples were homogenized in potassium phosphate buffer (0.1 M, pH 6.5) in a 1:10 dilution. One part of the homogenate was used to evaluate reduced glutathione (GSH) levels, and the other part was centrifuged at 9700 rotations per minute (rpm) in a micro-high-speed refrigerated centrifuge (VS-15000 CFNII, Vision Scientific, Daejeon, South Korea) for 20 min. The supernatant was used to evaluate lipid peroxidation (LPO) levels.
Evaluation of reduced glutathione levels
To evaluate GSH levels, 100 μl of the homogenate was mixed with 80 μl of 12.5% trichloroacetic acid and centrifuged at 6000 rpm for 15 min at 4°C. Afterward, 20 μl of the supernatant was mixed with 280 μl of Tris buffer (0.4 M, pH 8.9) and 5 μl of 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB; 0.01 M) according to the protocol of Sedlak and Lindsay [26] , with minor modifications. Absorbance was read at 415 nm using a multi-mode microplate reader (BioTek Synergy HT, BioTek Instruments, Winooski, VT, USA). The individual values were then interpolated in a standard curve of GSH (0.375-3 μg) to verify the linearity of the reaction (r 2 must be N0.99), and the values were divided by a correction factor. The results are expressed as μg of GSH per g of tissue.
Evaluation of lipid peroxidation levels
Lipid peroxidation levels were measured according to the method of Jiang et al. [27] , with minor modifications. Initially, 100 μl of the supernatant was suspended in 100 μl of methanol, vortexed, and then centrifuged at 5000 rpm for 5 min at 4°C. Afterward, 100 μl of the supernatant was added to 900 μl of FOX2 reagent (4 mM BHT, 250 μM FeSO 4 , 250 mM H 2 SO 4 , and 100 mM xylenol orange). The samples were vortexed and incubated in the dark for 30 min at room temperature. Absorbance was read at 560 nm using a multi-mode microplate reader (BioTek Synergy HT, BioTek Instruments, Winooski, VT, USA). The results are expressed as mmol of hydroperoxides per mg of tissue. 
Statistical analysis
For all of the experiments, two-way analysis of variance (ANOVA) was used. Significant main effects or interactions in the ANOVA were followed by the Newman-Keuls post hoc test. The Pearson correlation coefficient (r) was performed to measure the correlation between locomotor activity and oxidative stress parameters. The data are expressed as mean ± SEM. Values of p b 0.05 were considered statistically significant. All analysis were performed using Statistica 7.0 (Statsoft Inc., Tulsa, USA) software. Table 1 ). Independent of treatment, methylphenidate increased GHS levels (p b 0.01). Quercetin (2.5 and 5.0 mg/kg) increased GSH levels independent of methylphenidate treatment (both p b 0.05).
3.2.1.3. Striatum. There is a significant main effect of methylphenidate (F 1,33 = 9.455, p b 0.05) but no effect of acute treatment (F 6,33 = 1.423, p N 0.05) and no methylphenidate × acute treatment interaction (F 6,33 = 0.136, p b 0.05; Table 1 ). Methylphenidate decreased GSH levels independent of treatment (p b 0.01). Table 1 ). Independent of treatment, methylphenidate increased LPO levels (p b 0.01). Quercetin (10 and 40 mg/kg) increased LPO levels independent of methylphenidate treatment (both p b 0.01). Fig. 3 ). Lithium and 5.0 and 40 mg/kg quercetin increased GSH levels independent of methylphenidate administration. 3.2.5. Correlation between methylphenidate-induced hyperlocomotion and reduced glutathione and lipid peroxidation levels in the hippocampus, striatum, and prefrontal cortex Considering all animals from the acute treatment protocol, a positive correlation was found between hyperlocomotion and LPO levels in the PFC (r = 0.48, p b 0.001) and hippocampus (r = 0.56, p b 0.001), and a positive correlation was found between hyperlocomotion and GSH levels in the PFC (r = 0.32, p b 0.05) and hippocampus (r = 0.46, p b 0.001) ( Table 2) .
Considering all animals from the chronic treatment protocol, a positive correlation was found between hyperlocomotion and GSH levels in the hippocampus (r = 0.37, p b 0.01), and a positive correlation was found between hyperlocomotion and LPO levels in the PFC (r = 0.26, p b 0.05) and striatum (r = 0.32, p b 0.05). A negative correlation was found between hyperlocomotion and GSH levels in the striatum (r = −0.36, p b 0.01).
Discussion
The present study showed that chronic but not acute treatment with 10 and 40 mg/kg quercetin blocked methylphenidate-induced hyperlocomotion. Both acute and chronic lithium treatment blocked methylphenidate-induced hyperlocomotion, which is consistent with its clinical antimanic effect. These effects were seen at doses that did not alter spontaneous locomotor activity. The results with lithium indicate the sensitivity and validity of the procedure. The effects of quercetin on methylphenidate-induced hyperlocomotion indicated an antimanic-like effect of chronic quercetin administration. Diazepam was used as a negative control, but acute and chronic diazepam treatment also blocked methylphenidate-induced hyperlocomotion. However, in both experiments, diazepam alone reduced locomotor activity, suggesting a sedative effect instead of an antimanic-like effect of diazepam [11] . Psychostimulant-induced hyperlocomotion is the most frequently used animal model of mania [28] . This pharmacological induction of manic-like behavior is reliable and has face, construct, and predictive validity [28, 29] . Psychostimulants that are able to increase the levels of dopamine induce behavioral effects that resemble mania, such as hyperlocomotion [30] . Mania has been related to an increase in dopaminergic activity [31] . A reduction of dopaminergic activity ameliorates the symptoms of mania [32] . Lithium is able to decrease dopaminergic transmission [33] . Methylphenidate, which blocks dopamine reuptake, was shown to induce hyperlocomotion, which was prevented by lithium, valproate carbamazepine, and antipsychotic drug administration [13, 14, 15, 16, 17, 18] . Moreover, methylphenidate can induce manic-like symptoms in humans [34, 35, 36, 37] .
However, other factors are also involved in manic-like behavior that is induced by methylphenidate, such as oxidative stress. Burrows et al. [38] reported that the administration of psychostimulants that increase dopaminergic neurotransmission can also cause oxidative stress. Shanthakumar et al. [39] showed that mice that were treated with methylphenidate exhibited hyperlocomotion and increased oxidative stress, which were blocked by lithium treatment.
The main antioxidant molecule in the brain is GSH, which participates in many cellular reactions. Reduced glutathione is involved in the regulation of lipid, glucose, and amino acid utilization. It is also involved in several chemical reactions that are associated with liver function, immunity, cellular physiology, and biosignaling pathways. However, the main function of GSH is its antioxidant activity. It effectively scavenges free radicals and other reactive oxygen species, removing hydrogen and lipid peroxides and preventing the oxidation of biomolecules [40] . Therefore, the depletion of GSH levels may have deleterious effects. Gawryluk et al. [41] found lower levels of GSH in the post-mortem prefrontal cortex of bipolar disorder patients compared with brain samples from individuals with no psychiatric illnesses. Macêdo et al. [42] found that lisdexamphetamine dimesylate induced manic-like behavior in rats and decreased GSH content in the PFC, hippocampus, and striatum in rats, and these effects were reversed by lithium.
In the present study, methylphenidate increased GSH levels in the PFC and hippocampus but decreased GSH levels in the striatum. Pearson's correlation indicated a negative correlation between hyperlocomotion and GSH levels in the striatum in all of the animals that were subjected to the chronic treatment protocol. The heterogeneous effects of methylphenidate on GSH levels are not unusual or uncommon. Other research groups also reported diverse results regarding the effects of drugs that depend on dose, brain site, the specific oxidative stress parameter [7, 39, 43, 44] . Our results showed that quercetin did not reverse the methylphenidate-induced decrease in GSH levels, but in some cases quercetin increased GSH levels compared with controls (vehicle + vehicle).
Emerging data indicate that oxidative stress may play a role in psychiatric illnesses, including bipolar disorder. Low levels of free radicals or reactive oxygen/nitrogen species are considered normal, but high levels can damage and oxidize nucleic acids, carbohydrates, and lipids [45] . Lipids are the major components of cell membranes, including neuronal membranes, and their peroxidation and alterations that generate hydroperoxides can greatly affect brain function [45] . The levels of LPO increase during manic episodes. Lithium, which is used to treat mania in bipolar disorder, inhibits LPO and protein oxidation, suggesting that it has neuroprotective effects against oxidative stress that may be related to its antimanic effect [46] . Lipid peroxidation that results from uncompensated oxidative stress is an important finding in bipolar disorder, regardless of the stage of the illness [47, 48] . Macêdo et al. [42] also found an increase in LPO levels in the PFC, hippocampus, and striatum in rats in an animal model of psychostimulant-induced hyperlocomotion. Lithium treatment blocked this increase in oxidative stress.
In the present study, the effects of methylphenidate on oxidative stress were heterogeneous. Pearson's correlation indicated a positive correlation between hyperlocomotion and LPO levels in the PFC and hippocampus. Overall, methylphenidate administration increased LPO levels in the PFC, hippocampus, and striatum. Acute lithium administration blocked the methylphenidate-induced increase in LPO only in the hippocampus. Acute diazepam administration blocked the methylphenidate-induced increase in LPO in the hippocampus, although at a dose that also decreased spontaneous locomotor activity. Chronic treatment with 10 mg/kg quercetin blocked the methylphenidate-induced increase in LPO levels in the PFC. Chronic treatment with lithium, diazepam, and all doses of quercetin blocked the methylphenidate-induced increase in LPO levels in the striatum. These results suggest that treatments that prevent methylphenidate-induced hyperlocomotion also have antioxidant effects.
However, such effects have been inconsistent. Arunagiri et al. [16] showed that methylphenidate decreased GSH levels and increased LPO levels in whole brain homogenates, and lithium treatment restored GSH levels and reduced LPO levels. Various other studies reported heterogeneous results concerning the effects of drugs on oxidative stress in the brain [7, 39, 43, 44] . The results have varied, depending on the treatment protocol, drug, dose, and brain site, among other factors. Martins et al. [49] found that methylphenidate administration reduced LPO levels in the PFC and striatum in rats. At lower doses, methylphenidate decreased LPO levels in the hippocampus. At higher doses, methylphenidate increased LPO levels in the hippocampus. Although our study found heterogeneous results, chronic treatment with lithium and quercetin reduced antimanic-like behavior and reduced LPO levels in the striatum. The present and previous findings reinforce the putative role of oxidative stress in mania.
Overall, the present results indicated that chronic quercetin decreased methylphenidate-induced oxidative stress and hyperlocomotion, whereas acute treatment did not. This partially agrees with previous data that showed that acute quercetin treatment attenuated the increase in oxidative stress that was induced by sleep deprivation, which also led to an increase in locomotor activity [21] . The disagreement between these studies may be related to the different animal models of mania that were used, which reinforces the importance of using more than one model to evaluate the potential antimanic-like effects of drugs. Altogether, these data indicate an acute and chronic effect of quercetin on maniclike behavior.
Previous studies have shown that increases in dopaminergic transmission and consequent hyperlocomotion involve the activation of signaling pathways that are related to such enzymes as PKC [10] . Both lithium and quercetin exert antioxidant effects, and both are known to exert inhibitory effects on the activity of PKC [5] . Our research group showed that myricitrin, a flavonoid that has antioxidant and PKC-inhibitory actions, blocked oxidative stress and manic-like behavior [50, 51] . The pathophysiology of mania in bipolar disorder involves increases in both PKC activity and oxidative stress [47, 48, 52] . We hypothesized that quercetin might have antimanic properties. Indeed, chronic treatment with 10 and 40 mg/kg quercetin blocked methylphenidate-induced hyperlocomotion. In some cases, quercetin also restored GSH levels and decreased LPO levels after methylphenidate administration, similar to the effects of lithium. This indicates that the antimanic-like effect of quercetin may be linked to a decrease in oxidative stress.
PKC regulates several potential targets related to mood disorders, such as DAT, SERT, GSK-3beta, adenilate cyclase, NMDA receptors, GAP-43, BDNF and neurogenesis [10] . Specifically in DA system, PKC regulated DAT trafficking to cell surface, modulating DA neurotransmission [53, 54] Moreover, PKC also affects drug induced DA efflux [55] . Thus, increased PKC activity is associated with enhanced in dopaminergic activity. It was proposed that DA transmission is increased in mania [31] , which can result in an augment in DA metabolism, generating DA metabolites rising. Quinone oxidative products of DA metabolites can generate toxic effects and induce oxidative stress [56] . In this line, psychostimulants (amphetamine and fenproporex) act by augmenting DA transmission and they induce hyperlocomotion and oxidative stress increasing [11, 57] . Thus, quercetin can exert its antimanic-like effect reducing oxidative stress and PKC activity.
Quercetin has already been tested in clinical trials with regard to its anti-inflammatory effect. The effective dose range in the present study was within the dose range (40-240 mg/day) that was used in clinical trials [22] .
Conclusions
Chronic quercetin treatment blocked methylphenidate-induced hyperlocomotion in mice, indicating an antimanic-like effect. Moreover, chronic quercetin treatment blocked the methylphenidate-induced increase in oxidative stress indices. These results corroborate previous data that indicated that quercetin may have antimanic-like effects that are associated with an antioxidant effect. Furthermore, the present findings extend previous data that showed that no tolerance to this effect develops after repeated administration, which is an important issue for the treatment of mania. The putative anti-inflammatory and antioxidant effects of quercetin have been tested in clinical trials, and quercetin may be an interesting candidate as a new antimanic drug.
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